transducin beta like 1 Y-linkedGenealiases: DFNY2 · TBL1
Q-omics provides the consensus-scored TBL1Y profile across patient tissues and cancer cell-line models. TBL1Y expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TBL1Y is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, TBL1Y RNA expression shows 8,107 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where TBL1Y shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBL1Y — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBL1Y survival associations across molecular data types. TBL1Y RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBL1Y RNA expression–survival associations across cancer types. High TBL1Y expression shows unfavorable associations in OV, THCA and UCEC, but favorable associations in KIRC, UVM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TBL1Y RNA expression.
This table summarizes TBL1Y tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TBL1Y. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBL1Y shows lower tumor expression in KICH, KIRC, KIRP, THCA, ESCA and LUAD. The KICH box plot shows higher TBL1Y RNA expression in normal versus tumor tissue (log2 FC = −1.943, t-test p < 0.001).
This table shows molecular features associated with TBL1Y in patient tissues and cancer cell lines. In patient samples, TBL1Y shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TBL1Y RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
